Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

New Resource Available to Help Assess Value of Drug- Based Oncology Therapies

TOP - September 2011 Vol 4, No 6 published on September 21, 2011

Oncology pharmacists have a new tool for helping them better treat their patients. The Association of Community Cancer Centers (ACCC) has released a new publication, “The Practical Cancer Pharmacy,” designed to help hospital cancer pharmacy and financial teams move past the short-term orientation of considering only cost when deciding which drugs to purchase.

The Practical Cancer Pharmacy“Pharmacists and other providers need to really understand the value that these products have for their patients, which may be different than the assessment of them on a national level or from the payer’s perspective,” George Silberman, a consultant who worked with the advisory board of the ACCC to write the workbook, told The Oncology Pharmacist. “The acquisition price may not reflect the cost to the institution. For example, an oral product would require fewer resources than an IV product. Those resources need to be factored in.”

The workbook is accompanied by 3 webinars, which will cover a practical approach to pharmacoeconomics. We now have more anticancer options than ever before. ACCC’s goal is to help hospital cancer programs accurately assess the true value associated with these drug-based therapies.

“As hospitals continue to face increasing pressures to provide the highest quality care for the lowest possible cost, understanding the true value of the health services they provide to patients is critical for their continued viability,” said ACCC president Thomas L. Whittaker, MD.

With healthcare reform and increased cost-consciousness, oncology pharmacists are faced with continued pressures to adhere to budgetary restrictions and keep down the costs of drugbased therapy. Whereas some pharmacists may approach this task with the required level of sophistication, some may translate the requirement to keep costs down into an overly simplistic rule of selecting drugs with the lowest purchase price.

An emphasis solely on purchase price ignores the reality that there are numerous other “costs” associated with drug use, including dosing, treatment side effects, and costs needed to support the use of a drug. Consequently, providers who rely entirely on drugs that initially cost less often may spend considerably more because of the additional staff, space, and supportive resources that these drugs can require.

Timothy Tyler, who is director of pharmacy services at the Desert Regional Medical Center in Palm Springs, California, helped develop the workbook. He said this type of tool may be highly beneficial in preserving the most appropriate treatments for each individual patient. “One of the biggest concerns facing pharmacists today is the drug shortage. It is impacting everyone in the pharmacy,” Tyler said in an interview with The Oncology Pharmacist. “In the current scenario with drug shortages, it helps to look at things through an economic viewpoint and offer analyses.”

“The Practical Cancer Pharmacy” begins with an overview of pharmacoeconomics. Using the principle that the best way to learn is to do, the workbook includes an exercise in which readers will conduct a pharmacoeconomic analysis. The text, presented in nontechnical terms, makes the subject matter more accessible to those with little familiarity with formal methods for health technology assessment. Readers gain sufficient grounding in the discipline so that they can both understand pharmacoeconomic studies done by others and contribute to pharmacoeconomic analyses undertaken at their institutions.

The workbook explores the 7 major steps involved in estimating the cost-utility of one oncology drug compared with another:

  1. What type of pharmacoeconomic analysis is best?
  2. How should the analysis be designed?
  3. Who is the client for results?
  4. How should the relevant factors be measured?
  5. Where do you get the data?
  6. How do you build the model and interpret results?
  7. How should you present the findings to decision makers?

Although no oncology drugs are mentioned by name, through a series of assignments the workbook helps the reader build a decision-analytic model to estimate the relative cost-utility of 2 hypothetical drugs indicated for recurrent, metastatic breast cancer patients. The discussion centers on measures of costs, outcomes, and patient preferences. In addition, the reader learns how to compute the cost-effectiveness ratios of 2 hypothetical antiemetics.

The publication and archived webinars are available through ACCC’s Center for Provider Education and ACCC’s Oncology Pharmacy Education Network (OPEN). They can be accessed at www.accc-cancer.org/openweb.

Related Items
Nurses May Help Drive Integration of Palliative Care for Radiation Therapy Patients
John Schieszer
Web Exclusives published on December 30, 2011 in Palliative Care
A Call for Improved Guidelines for Adult Cancer Survivors
John Schieszer
Web Exclusives published on December 30, 2011 in Survivorship
Higher Radiation Doses May Not Help Lung Cancer Patients Live Longer
John Schieszer
TOP - December 2011, Vol 4, No 8 published on December 21, 2011 in Conference Correspondent
Effects of Chemotherapy on Fertility May Be Underestimated Significantly
John Schieszer
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Supportive Care
Stress Linked to Breast Cancer Aggressiveness
John Schieszer
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Conference Correspondent
Genetic Differences Linked to Higher Risk, Severity of Prostate Cancer in African-American Men
John Schieszer
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Conference Correspondent
Secondary Breast Cancer Rates Higher in African-American Women
John Schieszer
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Conference Correspondent
Hospital Uniforms Often Contain Dangerous Bacteria
John Schieszer
TOP - September 2011 Vol 4, No 6 published on September 21, 2011 in Best Practices
Approved Sunitinib Dosing Recommended for Metastatic Renal Cell Carcinoma
John Schieszer
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Genitourinary Cancers
Postmenopausal Women with Breast Cancer Receiving an Aromatase Inhibitor May Be at Increased Risk for Bone Loss
John Schieszer
TOP - August 2010 Vol 3, No 5 published on September 24, 2010
Last modified: July 22, 2021